SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-065178
Filing Date
2023-11-20
Accepted
2023-11-20 17:00:12
Documents
14
Period of Report
2023-11-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20231114.htm   iXBRL 8-K 47111
2 EX-99.1 sabs-ex99_1.htm EX-99.1 11239
  Complete submission text file 0000950170-23-065178.txt   215963

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20231114_def.xml EX-101.DEF 13467
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20231114_pre.xml EX-101.PRE 12759
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20231114.xsd EX-101.SCH 3214
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20231114_lab.xml EX-101.LAB 17242
8 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20231114_htm.xml XML 6479
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 231423456
SIC: 2836 Biological Products, (No Diagnostic Substances)